- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01629303
Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation (CONSTIMOD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of constipation is 2-27% in Western countries. For patients failing medical treatment (laxatives, biofeedback), a surgical solution may be considered (subtotal colectomy). But results are variable and it puts them at risk of functional sequelae.
Sacral nerve modulation is a minimally invasive procedure compared with the standard surgical support (colectomy) and reversible, which consists in two stages. First, a 3-week temporary stimulation test allows verifying the efficacy of neuromodulation. If the test is positive, the stimulating electrode is definitely implanted. Risks related to the procedure (infection, pain) are much smaller than those associated with a conventional surgical support.
Non comparative studies conducted with 19 and 62 patients showed that 40-73% of implanted patients have an improvement of their constipation and could benefit of permanent implantation with good results in medium term.
The primary objective of the investigators study is to evaluate the short-term efficacy (percentage of responders at 2 months) of sacral nerve modulation in the treatment of severe chronic constipation.
This is a cross-over designed, double-blinded, French multicenter clinical trial, including two periods: 2 months of stimulation ON and 2 months of stimulation OFF. Between these two periods, a 15-days period of "wash-out" will be respected during which all patients will be in OFF mode (4.5 months in total). This period of 4.5 months will be extended by a follow-up period of 7 months during which all patients will be treated (stimulation ON).
If this trial showed efficiency of this procedure, patients with severe refractory constipation could benefit of a sacral nerve modulation test before considering a surgical treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33075
- Service d'hépato-gastroentérologie et oncologie digestive
-
Clermont Ferrand, France, 63000
- Service d'hépato-gastroentérologie - CHU Estaing
-
Colombes, France, 92000
- Service de gastroentérologie - AP HP
-
Grenoble, France, 38000
- Service de Chirurgie générale - CHU de Grenoble
-
Lyon, France, 69000
- Service d'exploration fonctionnelle digestive -Hospices Civils de Lyon
-
Marseille, France, 13000
- Service de gastroentérologie - hopital nord -AP-HM
-
Nantes, France, 44000
- : Clinique de chirurgie digestive et endocrinienne. Institut des Maladies de l'Appareil Digestif (IMAD
-
Rennes, France, 35000
- SMAD CHU Pontchaillou -Rennes
-
Rouen, France, 76000
- Service de physiologie digestive, urinaire, respiratoire et sportive - CHU de rouen
-
Tours, France, 37000
- Service d'hépato-gastroentérologie et explorations fonctionnelles digestives - CHU de Tours
-
-
Limoges
-
CHU de Limoges, Limoges, France, 87000
- Service d' Hépato-gastro-entérologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years old
Constipation defined by at least two of the following criteria :
- Frequency of 2 stools or less per week
- Severe outlet constipation, i.e. need to use digital extraction or enemas more than 25% of time
- Sensation of incomplete evacuation more than 25% of time
- Refractory constipation since at least 1 year to medical treatment (drug treatment and/or biofeedback) conducted in the centre (failure or intolerance to laxative osmotic treatments, stimulants, and prucalopride) for which surgery is discussed
- Patients supported in the centre for at least 3 months before inclusion
- Patients having social security system
- Patients having read and signed informed consent form
Exclusion Criteria:
- Constipation secondary to ano-rectal malformation, surgical sequel, colorectal or anal organic lesions, or pelvi-perineal static disorder indicated for surgical treatment
- Constipation secondary to neurological pathology and/or concomitant treatments intake (opiates, anticholinergic agents)
- Partial colectomy history
- Patients in whom implantation of stimulating electrode is impossible due to anatomical reasons (e.g. sacral agenesis)
- Pregnant female patients or with childbearing potential without adequate contraceptive barrier (oestrogen-progesterone contraceptives or intra-uterine device)
- Skin disease associated with a risk of infection - in the opinion of the investigator
- Patient with pacemaker or defibrillator
- Patient exposed to resonance magnetic imaging
- Psychiatric disease incompatible with use of the treatment - in the opinion of the investigator
- Patient misunderstanding oral and written French language
- Patient participating to another study
- Patients who don't complete the first diary without missing data (concerning items used to define the primary endpoint)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Arm on-off
After the definitive implantation, stimulators are placed in position OFF during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks |
After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks. Then all the stimulators are switched OFF (both first and second arms) for 15 days. Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks |
EXPERIMENTAL: Arm off-on
After the definitive implantation, stimulators are placed in position ON during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks |
After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks. Then all the stimulators are switched OFF (both first and second arms) for 15 days. Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients showing a positive response to sacral nerve stimulation at 2 months
Time Frame: 2 months of the stimualtion period
|
Percentage of patients showing a positive response to sacral nerve stimulation during the period " ON " compared with the period " OFF " based on an objective assessment of the number of feces and their characteristics
|
2 months of the stimualtion period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical characteristics, manometry data, Wexner score of responders to stimulation during the temporary stimulation test (period before the permanent implantation)
Time Frame: 3 weeks between temporary and permanent implantations
|
3 weeks between temporary and permanent implantations
|
|
Clinical characteristics, manometry data, Wexner score of responders to short-term stimulation
Time Frame: 2 months after permanent implantation
|
2 months after permanent implantation
|
|
Efficacy of neuromodulation
Time Frame: 1 year after permanent implantation
|
Efficacy of neuromodulation (percentage of positive responders) at 1 year
|
1 year after permanent implantation
|
Manometry data, Wexner, QoL and EVA scores, time of colonic transit of responders to prolonged stimulation
Time Frame: 1 year after permanent implantation
|
1 year after permanent implantation
|
|
To evaluate the investigator opinion about the neuromodulation response, using the patient diary.
Time Frame: 1 year after permanent implantation
|
1 year after permanent implantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Frank ZERBIB, Professor, University Hospital, Bordeaux
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2011/23
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Constipation
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
usMIMA S.L.University of York; County Durham and Darlington NHS Foundation TrustNot yet recruitingConstipation | Constipation-predominant Irritable Bowel Syndrome | Constipation - Functional | Constipation Chronic Idiopathic | Constipation; Neurogenic
-
Institute of Medical Sciences and SUM HospitalNot yet recruitingFunctional Constipation | Constipation - Functional | Constipation Chronic Idiopathic | Fecal Impaction | Pediatric Functional ConstipationIndia
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
ProgenaBiomeRecruitingConstipation | Constipation - Functional | Constipation Chronic Idiopathic | Constipation (Excl Faecal Impaction)United States
-
Pamukkale UniversityRecruiting
-
Shanghai University of Traditional Chinese MedicineLonghua Hospital; Shanghai Municipal Hospital of Traditional Chinese MedicineRecruiting
-
Universidade Nova de LisboaCINTESIS - Center for Health Technology and Services ResearchRecruiting
Clinical Trials on sacral nerve modulation
-
Seinajoki Central HospitalTurku University Hospital; Helsinki University Central Hospital; Oulu University... and other collaboratorsRecruiting
-
Cantonal Hospital of St. GallenCompletedConstipation | Fecal Incontinence
-
University Hospital, AkershusEnrolling by invitationStoma Malfunction
-
MedtronicNeuroMedtronic France SASCompletedUrinary Incontinence | Urinary Retention | Over Active BladderFrance
-
Cantonal Hospital of St. GallenCompletedFecal IncontinenceSwitzerland
-
Thync Global, Inc.ethica Clinical Research Inc.UnknownPlaque PsoriasisUnited States
-
Ruijin HospitalUnknown
-
University of Lausanne HospitalsWithdrawnFecal IncontinenceSwitzerland
-
MedtronicNeuroMedtronic France SAS; Medtronic MCRICompletedFecal IncontinenceFrance
-
Micron Medical CorporationWithdrawnUrinary Incontinence, UrgeUnited States